UPB:NASDAQUpstream Bio, Inc. Analysis
Data as of 2026-09-05 - not real-time
$6.01
Latest Price
9/10Risk
Risk Level: High
Executive Summary
The moving-average structure behind Upstream Bio, Inc. is bearish at $6.01, with short-term averages lagging the long-term ones. It has lost 6.2% over the past 30 days. Relative strength is 36.6 — approaching oversold — and the MACD signal is bearish. Price has been bracketed by support at $5.77 and resistance at $7.70.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 457.4% above where the shares trade now. Revenue is contracting at 17.5%.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 65.4%, a beta of 1.14 and a maximum drawdown of 81.8%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
This one splits by horizon — sell in the near term, hold further out, at 2/10 long-term conviction.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 457.4% above where the shares trade now. Revenue is contracting at 17.5%.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 65.4%, a beta of 1.14 and a maximum drawdown of 81.8%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
This one splits by horizon — sell in the near term, hold further out, at 2/10 long-term conviction.
Top Market Events
- Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with...Yahoo Finance24dUpstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued ProgressThe above...
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 13.89
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 13.89
- Analyst targets imply +457.4% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 2/10
Key Factors
- Analyst targets imply +457.4% versus the current price
- Negative return on equity of -46.1%
- Revenue contracting at -17.5%
Key Metrics & Analysis
Financial Health
Revenue Growth-17.50%
P/E Ratio-2.1
ROE-46.05%
ROA-30.28%
Debt/Equity0.35
P/B Ratio1.1
Op. Cash Flow$-136344000
Free Cash Flow$-86616000
Industry P/E30.6
Technical Analysis
TrendBearish
RSI36.6
Support$5.77
Resistance$7.70
MA 20$6.84
MA 50$6.93
MA 200$13.89
MACDBearish
VolumeStable
Fear & Greed Index95.48
Valuation
Target Price$33.50
Upside/Downside457.40%
GradeFair
TypeBlend
Risk Assessment
Beta1.14
Volatility65.36%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.